Reasons for not receiving the HPV vaccine among eligible adults: Lack of knowledge and of provider recommendations contribute more than safety and insurance concerns

Joël Fokom Domgue1,2,3 | Sonia A. Cunningham1 | Robert K. Yu4 | Sanjay Shete1,2,4

1Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Division of Cancer Prevention and Population Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence
Sanjay Shete, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1400 Pressler Dr, Unit 1400, Houston, TX 77030, USA.
Email: sshete@mdanderson.org

Funding information
National Cancer Institute, Grant/Award Number: P30CA016672; Betty B. Marcus Chair in Cancer Prevention; Duncan Family Institute for Cancer Prevention and Risk Assessment; Division of Cancer Prevention, National Cancer Institute, Grant/Award Number: 5P30CA016672, sub-project ID, 5697; Cancer Prevention and Research Institute of Texas, Grant/Award Number: RP170259

Abstract
Background: The upward trends of vaccine exemptions in Texas are alarming. While HPV vaccine rates in this State are among the lowest nationwide, factors that contribute to the low HPV vaccination uptake among adults remain unknown. In this study, we examined the main reasons for not receiving HPV vaccination among age-eligible adults.

Methods: The Texas health screening survey (2018), a multistage area probability design-based survey of a representative sample of Texas residents, was used to identify 907 eligible adults (age ≥ 18 years) respondents, including 724 women aged ≤ 26 years in 2007 (≤38 years in 2018), and 183 men aged ≤ 21 years in 2011 (≤28 years in 2018). Participants who reported having never received an HPV shot, where asked the main reason for not receiving the vaccine.

Results: Overall, 58.5% (95%CI: 55.1-62.0) of vaccine eligible adults reported having never received the HPV vaccine. The most commonly reported reasons for not receiving it were: did not know about the vaccine (18.5% (14.9-22.1)), and provider did not recommend (14.1% (10.9-17.4)). In contrast, commonly perceived reasons such as: safety concerns (7.2% (4.8-9.5)), lack of insurance (3.4% (1.7-5.1), and concerns about increasing sexual activity if vaccinated (0.2% (0.0-0.5)), were less frequently reported.

Conclusion: Among vaccine-eligible adults, safety and sexuality concerns do not appear to be the prime factors underlying low HPV vaccination rates. Rather than emphasizing them, educational interventions should aim at improving vaccine's knowledge, and enhancing provider recommendations on the necessity of HPV vaccination.

KEYWORDS
adult population, HPV vaccination, necessity, reasons, safety, Texas
1 | INTRODUCTION

In the United States (US), the human papillomavirus (HPV) causes about 33,700 cancers each year, including cancers of the cervix, vagina, vulva, oropharynx, and anus. Following approval by the Food and Drug Administration (FDA), the American Committee on Immunization Practices (ACIP) recommended HPV vaccination for women in 2007 and for men in 2011. Despite constant efforts to promote knowledge of and accessibility to HPV vaccine, uptake in the US remains suboptimal.

Parental approval plays a key role in receipt of HPV vaccines by minor children. When children become legally adults (≥18 years of age), however, they no longer need approval from their parents/guardians to get vaccinated. Until 2018, HPV vaccination was recommended for US adults who have not previously been adequately immunized, through age 21 for men and 26 for women. Despite these guidelines, HPV vaccination coverage in eligible adults remains low in the US. In 2016, only 8.6% of women and 2.7% of men aged 19-26 years who had not received HPV vaccination prior to age 19, reported having had at least one dose of HPV vaccine. This is a matter of concern, as 64% to 82% of incident HPV DNA detected in mid-age US adults (25 to 60 years of age) who engage in new sexual partnerships is attributable to newly acquired infection.

There is a strong body of evidence suggesting that HPV vaccine is safe and effective in preventing HPV infection and HPV-related disease in both teenagers and older age groups. Based on these data, the FDA approved the expanded use of HPV vaccine in 2018 to include individuals 27 through 45 years. Considering the increasing incidence of HPV-associated cancers in the US, particularly oropharyngeal and anal cancers for which population-based screening is not endorsed, the ACIP recently recommended HPV vaccination in this age group as part of the shared decision-making process between patients and clinicians. This provides additional opportunities to people who did not receive the vaccine as minors, to benefit from it later in their life. In contrast to the compelling literature examining parents’ reasons for not consenting their children to receive HPV vaccination, little is known about the reasons why eligible, independent adults still do not get the HPV vaccine.

In the state of Texas, the second most populated region of the US, the proportion of parents/guardians who exempt their children from vaccination for nonmedical reasons has risen over the last decade, to the point where public health officials anticipate resurging outbreaks of certain preventable diseases among vulnerable populations. With only 43.5% of adolescents being up-to-date on their HPV vaccine series in 2018, Texas is lagging behind most US states on HPV vaccination. The rates are even lower among vaccine-eligible adults. However, factors that contribute to the suboptimal HPV vaccine uptake in this group have not been previously assessed from an individual’s perspective. In this study, we examined: (i) the proportion and characteristics of vaccine-eligible adults in Texas who have never received HPV vaccine; and (ii) their reasons for not getting vaccinated. Understanding these motivations may help identify effective interventions to improve HPV vaccine coverage in this population.

2 | METHODS

2.1 | Study population and recruitment procedure

Our study population was selected from a representative sample of the Texas population; the enrolment procedure has been described in detail elsewhere. Briefly, a nonprobability sample of 2050 respondents to the Texas health screening survey was collected between 5 February and 5 March 2018, using strata set to mirror Texas demographics for sex, ethnicity, race, and income. However, oversampling of non-Hispanic Blacks (NHBs) was conducted to ensure more accurate estimation in this minority group. The non-Hispanic White (NHW) category consisted of those selecting White as the sole race and the NHB category as those selecting Black/African American (either alone or in addition to other races). The recruitment target included 60% urban and 40% rural respondents, categorized by matching ZIP code to county designations. The instrument was prepared in English with Mexican Spanish translation with the help of Masterword Services, Inc, Houston, TX, and loaded into the Qualtrics online survey platform. Qualtrics managed hosting and compensation of the survey using opt-in panelists. The study protocol (PA16-0724) was approved by MD Anderson's Institutional Review Board. The present study focused on the population of adult respondents who were eligible for HPV vaccination, that is, women participants who were aged ≤ 26 years, and men participants who were aged ≤ 21 years when HPV vaccination was first recommended in the US (ie in 2007 for women and 2011 for men). Thus, our study sample consisted of 907 respondents, including 724 women aged ≤ 26 years in 2007 (≤38 years at the time of survey), and 183 men aged ≤ 21 years in 2011 (≤28 years at the time of survey).

2.2 | Outcome measures

The main outcomes for this study were: (a) self-reported receipt of HPV vaccine, and (b) self-reported reasons for not receiving HPV vaccine. To measure these outcomes, we adapted two validated questions from the National Immunization Survey-Teen (NIS-Teen). In the Texas
### TABLE 1  Characteristics of the Study Population according to HPV vaccination status

| Variables                          | Yes |       | No |       | Don’t know |       | Total |       |
|------------------------------------|-----|-------|----|-------|-----------|-------|-------|-------|
|                                   | N   | % (95% CI) | N | % (95% CI) | N | % (95% CI) | Na | % (95% CI) |
| Age (y)                           |     |       |    |       |           |       |       |       |
| 18-28                              | 151 | 78.9 (73.1-84.7) | 310 | 63.8 (59.5-68.1) | 131 | 79.4 (73.5-85.3) | 594 | 70.2 (67.1-73.3) |
| 29-38                              | 47  | 21.1 (15.3-26.9) | 220 | 36.2 (31.9-40.5) | 46  | 20.6 (14.7-26.5) | 313 | 29.8 (26.7-32.9) |
| Sex                                |     |       |    |       |           |       |       |       |
| Female                             | 165 | 73.3 (65.6-80.9) | 417 | 68.5 (63.8-73.3) | 140 | 65.7 (57.3-74.2) | 724 | 69.1 (65.4-72.7) |
| Male                               | 33  | 26.7 (19.1-34.4) | 113 | 31.5 (26.7-36.2) | 37  | 34.3 (25.8-42.7) | 183 | 30.9 (27.3-34.6) |
| Ethnicity/ Race                    |     |       |    |       |           |       |       |       |
| Black, non-Hispanic                | 41  | 10.1 (6.9-13.4) | 133 | 12.9 (10.6-15.3) | 39  | 10.4 (7.0-13.9) | 213 | 11.8 (10.1-13.5) |
| Hispanic                           | 108 | 56.4 (48.9-63.9) | 230 | 46.7 (42.1-51.3) | 99  | 59.4 (51.4-67.4) | 439 | 51.4 (47.9-54.9) |
| Others                             | 11  | 6.4 (2.6-10.3) | 45  | 8.8 (6.3-11.4) | 11  | 6.2 (2.5-10.0) | 67  | 7.8 (5.9-9.7) |
| White, non-Hispanic                | 38  | 27.0 (19.7-34.3) | 122 | 31.5 (27.0-36.1) | 28  | 23.9 (16.2-31.6) | 188 | 29.0 (25.5-32.5) |
| Born In USA                        |     |       |    |       |           |       |       |       |
| No                                 | 16  | 7.4 (3.8-11.1) | 44  | 7.5 (5.2-9.7) | 22  | 12.0 (7.0-17.0) | 82  | 8.3 (6.5-10.2) |
| Yes                                | 182 | 92.6 (88.9-96.2) | 486 | 92.5 (90.3-94.8) | 155 | 88.0 (83.0-93.0) | 825 | 91.7 (89.8-93.5) |
| Education                          |     |       |    |       |           |       |       |       |
| No greater than 12 y or completed high school | 52  | 27.7 (20.9-34.4) | 181 | 35.1 (30.6-39.5) | 88  | 51.6 (43.6-59.7) | 322 | 36.8 (33.3-40.2) |
| Post high school training or some college | 69  | 34.5 (27.3-41.7) | 191 | 35.1 (30.7-39.5) | 53  | 30.3 (22.7-37.8) | 313 | 33.9 (30.6-37.3) |
| College/Postgraduate               | 77  | 37.8 (30.5-45.1) | 157 | 29.9 (25.6-34.1) | 36  | 18.1 (12.1-24.0) | 271 | 29.3 (26.1-32.5) |
| Marital status                     |     |       |    |       |           |       |       |       |
| Single/Widowed/ Divorced/Separated | 119 | 61.0 (53.7-68.3) | 294 | 56.8 (52.2-61.4) | 109 | 61.8 (53.9-69.6) | 524 | 58.8 (55.3-62.3) |
| Living as Married/ Married         | 76  | 39.0 (31.7-46.3) | 227 | 43.2 (38.6-47.8) | 66  | 38.2 (30.4-46.1) | 369 | 41.2 (37.7-44.7) |
| Occupation                         |     |       |    |       |           |       |       |       |
| Employed                           | 122 | 59.7 (52.2-67.1) | 299 | 57.2 (52.7-61.8) | 73  | 40.4 (32.5-48.4) | 494 | 54.3 (50.8-57.9) |
| Homemaker/ Unemployed/ Disabled    | 48  | 24.0 (17.7-30.2) | 151 | 28.3 (24.2-32.4) | 69  | 40.2 (32.2-48.1) | 269 | 29.7 (26.5-32.9) |
| Student/Retired/Other              | 28  | 16.3 (10.3-22.4) | 78  | 14.5 (11.2-17.8) | 35  | 19.4 (13.1-25.8) | 142 | 15.9 (13.3-18.6) |
| Income                             |     |       |    |       |           |       |       |       |
| ≤$19 999                           | 46  | 24.1 (17.5-30.6) | 158 | 28.7 (24.6-32.9) | 73  | 40.6 (32.7-48.5) | 278 | 30.1 (26.9-33.3) |
| $20 000 to $49 999                 | 70  | 33.8 (26.8-40.9) | 169 | 31.3 (27.0-35.5) | 60  | 34.6 (26.8-42.4) | 299 | 32.4 (29.1-35.7) |
| $50 000 to $74 999                 | 36  | 18.3 (12.5-24.1) | 101 | 17.9 (14.5-21.3) | 21  | 11.4 (6.5-16.2) | 159 | 16.8 (14.2-19.3) |
| ≥$75 000                           | 46  | 23.8 (17.3-30.3) | 102 | 22.1 (18.1-26.2) | 23  | 13.4 (7.8-19.0) | 171 | 20.7 (17.7-23.7) |
| Residence                          |     |       |    |       |           |       |       |       |
| Rural                              | 59  | 34.9 (27.5-42.4) | 184 | 39.8 (35.2-44.4) | 69  | 43.1 (35.1-51.2) | 313 | 39.4 (35.9-43.0) |
| Urban                              | 139 | 65.1 (57.6-72.5) | 346 | 60.2 (55.6-64.8) | 108 | 56.9 (48.8-64.9) | 594 | 60.6 (57.0-64.1) |
| Hormonal contraception\textsuperscript{b} |     |       |    |       |           |       |       |       |
| No                                 | 40  | 16.2 (11.2-21.3) | 161 | 25.3 (21.6-29.0) | 50  | 23.7 (17.5-29.9) | 252 | 23.1 (20.4-25.8) |
| Yes                                | 125 | 57.1 (49.4-64.8) | 256 | 43.2 (38.7-47.7) | 90  | 42.0 (34.3-49.7) | 471 | 45.9 (42.4-49.4) |

(Continues)
Have you ever received the HPV shot, Cervarix, or Gardasil?

| Variables                  | Yes N | % (95% CI) | No N | % (95% CI) | Don’t know N | % (95% CI) | Total N | % (95% CI) |
|----------------------------|-------|------------|------|------------|--------------|------------|---------|------------|
| Smoking                    |       |            |      |            |              |            |         |            |
| Current smokers            | 43    | 22.4 (16.1-28.8) | 111  | 22.7 (18.7-26.7) | 41           | 25.0 (17.9-32.1) | 195       | 23.1 (20.0-26.1) |
| Former smokers             | 16    | 8.9 (4.6-13.3)   | 39   | 7.3 (5.0-9.7)    | 13           | 9.2 (4.2-14.2)   | 68        | 8.0 (6.1-10.0)   |
| Never smokers              | 139   | 68.6 (61.6-75.7) | 380  | 70.0 (65.6-74.3) | 123          | 65.8 (58.0-73.6) | 643       | 68.9 (65.5-72.2) |
| Health care coverage       |       |            |      |            |              |            |         |            |
| No                         | 58    | 31.5 (24.4-38.7) | 201  | 37.3 (32.8-41.8) | 84           | 47.0 (38.9-55.1) | 343       | 38.0 (34.5-41.4) |
| Yes                        | 139   | 68.5 (61.3-75.6) | 329  | 62.7 (58.2-67.2) | 93           | 53.0 (44.9-61.1) | 561       | 62.0 (58.6-65.5) |
| Hepatitis B Virus vaccination |     |            |      |            |              |            |         |            |
| No                         | 53    | 26.3 (19.6-32.9) | 350  | 66.9 (62.6-71.3) | 77           | 43.5 (35.4-51.5) | 480       | 53.4 (49.9-56.9) |
| Yes                        | 145   | 73.7 (67.1-80.4) | 180  | 33.1 (28.7-37.4) | 100          | 56.5 (48.5-64.6) | 425       | 46.4 (42.9-49.9) |
| Family History of any cancer |   |            |      |            |              |            |         |            |
| No                         | 48    | 22.2 (16.0-28.3) | 206  | 36.5 (32.1-41.0) | 53           | 28.1 (21.1-35.1) | 307       | 31.8 (28.5-35.0) |
| Not sure                   | 19    | 11.0 (5.8-16.2)  | 57   | 12.7 (9.4-16.0)  | 29           | 17.3 (11.0-23.5) | 105       | 13.2 (10.7-15.8) |
| Yes                        | 131   | 69.9 (59.7-74.0) | 266  | 50.8 (46.1-55.4) | 95           | 54.6 (46.6-62.6) | 492       | 55.0 (51.5-58.5) |

*2 participants did not provide information about their vaccination status.

*bMale participants did not respond to the question about hormonal contraception use.

health screening survey, these questions were directed to adult respondents who were or have been eligible to receive HPV vaccination. We first asked: (a) HPV is a common sexually transmitted virus that can cause genital warts and cervical and other types of cancer in men and women. Vaccines to prevent some HPV infections are available for men and women 9 - 26 years of age and are sometimes called the HPV shot, Cervarix, or Gardasil. Have you ever received the HPV shot, Cervarix, or Gardasil? The possible responses were: Yes/No/Don’t know. Participants who responded “No” were asked: (b) What is the main reason you have not received the HPV shot/vaccine? Possible responses were: Provider did not recommend (a), Did not know about the vaccine (b), Vaccine not needed or necessary (c), Not required to get the vaccine (d), Safety concerns (e), Provider indicated could vaccinate later (f), Uninsured or insurance doesn't fully cover shots, or copay or other costs too high (g), Shot could be painful (h), Vaccine not available (i), Difficulty making or getting to appointments/transportation issues (j), Concern about increasing sexual activity if receive shot (k), Not sexually active (l), Some other reason (m).

2.3 Covariates

Covariates were selected based on their potential influence on HPV vaccination uptake, including: socio-demographic factors of age, ethnicity/race, nativity, educational attainment, marital status, occupation, rurality, and household income; behavioral and mental factors; and health-related variables such as smoking status, health coverage, vaccination against Hepatitis B virus (HBV), hormonal contraception use, and family history of any cancer.

2.4 Statistical analysis

Data were weighted by ICF International, Inc, Fairfax, Virginia using a three-dimensional raking approach with iterative post-stratification based on sex, age, and race/ethnicity. We used means and standard deviation (continuous variables), weighted percentages and weighted 95% confidence interval (categorical variables), to describe the study population by HPV vaccination status. The reasons for having never received HPV vaccine were described according to the socio-demographic, health-related, and behavioral characteristics of the study population.

3 RESULTS

3.1 Characteristics of the study population

Table 1 describes the sociodemographic, health-related, and behavioral characteristics of the study sample, stratified by
HPV vaccine status. Of the 907 adult respondents included in this study, 198 [weighted percentage: 21.6% (weighted 95% confidence interval: 18.7-24.5%)] reported having ever received (at least one dose of) HPV vaccination, while 530 [58.5% (55.1-62.0%)] reported having never received this vaccine. The remaining 177 respondents [19.7% (16.8-22.5%)] reported not knowing if they have received the HPV vaccine.

HPV unvaccinated vs vaccinated respondents were more frequently: aged between 29 and 38 years [36.2% (31.9-40.5) vs 21.1% (15.3-26.9)]; males [31.5% (26.7-36.2) vs 26.7% (19.1-34.4)]; and NHWs [31.5% (27.0-36.1) vs 27.0% (19.7-34.3)]. HPV unvaccinated respondents were also more likely to: have a level of education not greater than 12 years [35.1% (30.6-39.5) vs 27.7% (20.9-34.4)]; and to reside in rural areas [39.8% (35.2-44.4) vs 34.9% (27.5-42.4)], compared with their vaccinated counterparts. (Table 1).

HPV unvaccinated respondents were less likely to: use hormonal contraception [43.2% (38.7-47.7) vs 57.1% (49.4-64.8)]; have health insurance [62.7% (58.2-67.2) vs 68.5% (61.3-75.6)]; be vaccinated against HBV [33.1% (28.7-37.4) vs 73.7% (67.1-80.4)]; and have a family history of cancer [50.8% (46.1-55.4) vs 66.9% (59.7-74.0)], compared with HPV vaccinated respondents. (Table 1).

3.2 | Reasons for having not received HPV vaccination

The main reasons for not getting the HPV vaccine differed by certain demographics including sex, ethnicity/race, and education and are reported in Figures 1-4 and the Table S1. Overall, the most frequently reported reasons were: “did not know about the vaccine” [18.5% (14.9-22.1)], “provider did not recommend” [14.2% (10.9-17.4)], “vaccine not needed or necessary” [13.8% (10.5-17.0)], and “not sexually active” [13.7% (10.5-16.9)] (Figure 1). Among women, the most common reason reported was ‘did not know about the vaccine’ [18.6% (14.7-22.6)], while among men, it was “not sexually active” [20.3% (12.7-27.9)] (Figure 2). Among NHWs, the most common reason was “vaccine not needed or necessary” [19.8% (12.2-27.5)], while it was “did not know about the vaccine” among Hispanics [20.1% (14.7-25.4)], and “not sexually active” among NHBs [24.7% (16.8-32.6)] (Figure 3). Among women with post-graduate education, the main reason reported was “provider did not recommend” [18.0% (11.3-24.7)]; while in women with not greater than high school education, the main reason was “did not know about the vaccine” [21.8% (15.3-28.4)] (Figure 4).
Some of the key least commonly reported reasons for not getting HPV vaccine included: “safety concerns” (7.2% (4.8-9.5)); “uninsured or insurance doesn’t fully cover shots” (3.4% (1.7-5.1)); “concerns about increasing sexual activity if receive the vaccine” [0.2% (0.0-0.5)]; and “difficulty making or getting to appointments, or transportation issues” (0.2% (0.0-0.4)) (Figure 1).

Reasons for not having received HPV vaccination described according to respondents’ characteristics age, origin of birth, marital status, occupational status, income, residency, use of hormonal contraception, smoking status, availability of health care, vaccination status for hepatitis B, and family history of cancer are reported in the Table S1.

4 | DISCUSSION

In this representative sample of adult Texas residents eligible for HPV vaccination, differences in socio-demographic, health-related, and behavioral characteristics were assessed between those who reported having ever received the HPV vaccine, and those who had never been vaccinated for HPV. Among eligible respondents who reported having not received HPV vaccination, we examined the reasons why they did not get the vaccine. To the best of our knowledge, this is the first study to assess individual’s reasons for not receiving HPV vaccine in the Texas adult population, a state with an alarmingly low HPV vaccine uptake.

Texas has experienced a 20-fold increase in nonmedical exemptions of vaccination for students since 2003 when exemptions for religious and personal beliefs were enacted.\textsuperscript{15,16} It is also one of the US States with the lowest HPV vaccination rates.\textsuperscript{18} The growing number of unvaccinated children arriving at Texas schools makes this state increasingly vulnerable to vaccine preventable outbreaks, according to a recent computer simulation.\textsuperscript{17} To help improve HPV vaccination rates, the Texas Medical Association recently joined with more than 40 other organizations to announce a renewed statewide immunization campaign to prevent HPV-related cancers.\textsuperscript{24} Despite these efforts, the impact that the rising number of anti-vaccine movements in the State have had on HPV vaccination coverage remains unknown. In order to examine the various reasons expressed by potential adult beneficiaries for the low HPV vaccination uptake, we administered this state-wide survey. Excluding participants who did not know their HPV vaccination status from our study population, 28.3% of women and 23.8% of men reported having ever received HPV vaccination. Based on the NHIS
data, HPV vaccination rates (at least one dose, ever) in 2016 were 48.5% among women aged 19 to 26 years, and 21.2% among men aged 19-21 years. Our study finding suggests that the lower HPV vaccination uptake among eligible adults in Texas, as compared to national rates, is driven by relatively lower HPV vaccination rate among adult vaccine-eligible women in Texas. Further studies are needed to understand barriers to HPV vaccination among women in Texas, and the reasons why they are less likely to be vaccinated for HPV than the average adult woman in the US.

HPV vaccination is routinely administered between 11 and 12 years with parental consent (2). However, catch-up immunization is recommended for both men and women through early adulthood, when individuals can independently make an informed choice about their health, including the decision about HPV vaccination. Thus, beyond parents’ perspectives, understanding individuals’ reasons for not receiving HPV vaccine is critical to improving vaccine uptake among eligible adults. In line with the recent FDA approval of HPV vaccine until age 45, the ACIP has recommended its use among US adults aged 27 to 45 years as part of shared clinical decision-making. In this context, it is essential to examine the reasons for non-initiation of HPV vaccination in the adult eligible population.

In our study sample, lack of knowledge about HPV vaccine, lack of provider’s recommendation, and perceived lack of necessity, were the most commonly reported reasons for not getting the vaccine. Interestingly, these reasons varied by certain demographics. Among women, the main reason for not getting the HPV vaccine was “did not know about the vaccine”, while among men, it was “not sexually active.” In a study assessing US parents’ reasons for lack of HPV vaccine initiation in their children, “safety concerns” was most frequently reported by parents of eligible girls vs “lack of necessity” by parents of eligible boys. It is well known that children’s values and practices are generally influenced by their parents’ beliefs and attitudes. However, our findings suggest that when they become adults, children may not necessarily give the same reasons as their parents for not receiving HPV vaccine. This highlights the need to develop adapted educational interventions to improve HPV vaccine uptake among eligible adults. The finding that sexual inactivity is a major reason for nonreceipt of HPV vaccine among men, may reflect their poorer understanding of the need to vaccinate before sexual debut. This is consistent with prior literature demonstrating less frequent, weaker, and less timely HPV vaccine recommendations for men compared to women, despite evidence that provider recommendation may have an even stronger impact on men’s vaccine initiation. Because providers who feel that they must discuss sexuality prior to recommending the vaccine tend to deliver lower quality,
less frequent recommendations, targeted interventions are needed to improve the impact of messages that providers deliver to patients. Only 0.2% of respondents (regardless of sex) reported concerns that the vaccine would increase their sexual activity. Therefore, providers’ concerns about discussing sexual activity is not relevant for vaccine-eligible adult individuals unlike for parents of vaccine-eligible adolescents, and thus, should not obstruct delivery of strong recommendations, especially among women.

Although the HPV vaccine was FDA approved to prevent cancer over a decade ago, eligible adults still report a lack of knowledge and understanding of its necessity. However, safety concerns, lack of insurance, transportation issues as well as some other concerns were less common in our study sample, suggesting that reasons commonly highlighted in mainstream media, such as anti-vaccination beliefs including religious objections are not the prime factors underlying individuals’ perception of HPV vaccination in Texas.

5 | STRENGTHS AND LIMITATIONS

Strengths of the study include its large sample size and the representativeness of the adult Texas population. The study is somewhat limited, however, in its ability to detect simultaneous reasons individuals may hold, as the question was framed to assess the “main” reason for not getting the vaccine. Because information about whether or how often eligible individuals visited a healthcare provider was not available, we could not distinguish between respondents with missed clinical opportunities for HPV vaccine recommendation, and those unexposed to provider recommendations. While the self-report of the vaccine status by study participants could yield a certain level of “misclassification” bias, substantial agreement between electronic medical reports of the vaccine status and self-reported data were noted for HPV vaccination.

6 | CONCLUSION

In this study, individual reasons for not receiving the HPV vaccine were assessed among eligible adults. A substantial proportion of age-eligible adults in Texas reported lack of knowledge or lack of provider recommendation as the main reasons for not receiving HPV vaccine. Rather than emphasizing on safety or sexual activity, educational interventions should focus on the necessity and awareness of HPV vaccination. Providers’ recommendation for HPV vaccine should be reinforced, and further adapted to older age groups.
ACKNOWLEDGMENT
This study was supported by the National Cancer Institute 5P30CA016672 Sub-Project ID: 5697 (PI: S Shete), a Cancer Prevention Fellowship supported by the Cancer Prevention and Research Institute of Texas (CPRIT) grant award, RP170259 (to JFD; PI: S Chang and S Shete), the Duncan Family Institute for Cancer Prevention and Risk Assessment (SS), and the Betty B. Marcus Chair in Cancer Prevention (SS).

CONFLICT OF INTEREST
The authors declare no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
Concept and Study Design: Fokom Domgue, Shete. Data Analysis: Yu. Interpretation of the data: Fokom Domgue, Cunningham, Yu, Shete. Initial Draft: Fokom Domgue. Critical revision of the manuscript for important intellectual content: Fokom Domgue, Cunningham, Yu, Shete. Obtained Funding and Study Supervision: Shete.

ROLE OF FUNDER/SPONSOR STATEMENT
The funders had no involvement in design and conduct of the study; analysis and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.

DATA AVAILABILITY STATEMENT
The data supporting findings of our study can be obtained from the corresponding author.

ORCID
Joël Fokom Domgue https://orcid.org/0000-0002-4722-9262
Sanjay Shete https://orcid.org/0000-0001-7622-376X

REFERENCES
1. CDC. How many cancers are linked with HPV each year? 2018. Available at: https://www.cdc.gov/cancer/hpv/statistics/cases.htm. Accessed May 5
2. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1-30.
3. Newman PA, Logie CH, Lacombe-Duncan A, et al. Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies. Bmj Open. 2018;8(4):e019206.
4. Kim DK, Hunter P. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(5):115-118.
5. Centers for Disease Control and Prevention. Vaccination coverage among adults in the United States, National Health Interview Survey. 2016. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaccine/Adult-vaccine/SMI/2016
6. Winer RL, Hughes JP, Feng Q, Stern JE, Xi LF, Koutsky LA. Incidence detection of high-risk human papillomavirus infections in a cohort of high-risk women aged 25–65 years. J Infect Dis. 2016;214(5):665-675.
7. Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitti PE. Contributions of recent and past sexual partnerships on incidence human papillomavirus detection: acquisition and reactivation in older women. Cancer Res. 2012;72(23):6183-6190.
8. Giuliani AR, Isaacs-Soriano K, Torres BN, et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)-The MAM Study. Vaccine. 2015;33(42):5640-5646.
9. Luna J, Plata M, Gonzalez M, et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil(TM) in adult women. PLoS One. 2013;8(12):e83431.
10. Castellsagué X, Muñoz N, Pitsaithilum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28-37.
11. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-includes-de-individuals-27-through-45-years-old. Accessed on May 5
12. Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in human papillomavirus-associated -cancers United States, 1999–2015. Mmwr-Morb Mortal W. 2018;67(33):918-924.
13. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. Mmwr-Morb Mortal W. 2019;68(32):698-702.
14. Gilkey MB, Calo WA, Marciniak MW, Brewer NT. Parents who refuse or delay HPV vaccine: differences in vaccination behavior, beliefs, and clinical communication preferences. Hum Vaccin Immunother. 2017;13(3):680-686.
15. Texas Department of Health and Human Services. Conscientious exemptions data - vaccination coverage levels. https://www.dshs. texas.gov/immunize/coverage/conscientious-exemptions-data-sm/#overview. Last accessed on October 5, 2019
16. Olive JK, Hotez PJ, Damania A, Nolan MS. The state of the antivaccine movement in the United States: A focused examination of nonmedical exemptions in states and counties. PLoS Med. 2018;15(6):e1002578.
17. Sinclair DR, Grefenstette JJ, Krauland A, et al. Forecasted size of measles outbreaks associated with vaccination exemptions for schoolchildren. JAMA Netw Open. 2019;2(8):e199768.
18. Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents Aged 13–17 years - United States, 2018. Mmwr-Morb Mortal W. 2019;68(33):718-723.
19. Cunningham SA, Yu R, Shete S. Differences in sun protection behaviors between rural and urban communities in Texas. J Rural Health. 2019;35(2):155-166.
20. Cunningham SA, Yu R, Shih T, et al. Cancer-related risk perceptions and beliefs in Texas: findings from a 2018 population-level survey. Cancer Epidemiol Biomarkers Prev. 2019;28(3):486-494.
21. Definitions of County Designations. Texas health and human services. Available at: https://www.dshs.texas.gov/chs/hprr/counties.shtm. Accessed on: February 13.
22. Texas ZIP Codes. Available at: https://www.zip-codes.com/state/tx.asp. accessed on: February 13
23. Mercer A, Lau A, Kennedy C. Pew Research Center. For weighting online opt-in samples, what matters most? Available at: http://assets.pewresearch.org/wp-content/uploads/sites/12/2018/01/26170902/Weighting-Online-Opt-In-Samples.pdf. Accessed on: July 23, 2018. 2018
24. Texas Medical Association. Get texas out of the HPV vaccine cellar. Available at: https://www.texmed.org/TexasMedicineDetail.aspx?id=47894. Last accessed October 5, 2019
25. Beavis A, Krakow M, Levinson K, Rositch AF. Reasons for lack of HPV vaccine initiation in NIS-teen over time: shifting the focus from gender and sexuality to necessity and safety. J Adolesc Health. 2018;63(5):652-656.
26. Chang WG, Park YS, Kim U. The influence of parent-child relationship and self-efficacy on quality of life among university students and their parents. Int J Psychol. 2008;43(3–4):308.
27. Fernandez LC. Why our children turn out to be the way they are: the genuine influence of parents on the personality of their children. Liberte. 2000;42(1):128-134.
28. Gilkey MB, Mcree AL. Provider communication about HPV vaccination: a systematic review. Hum Vacc Immunother. 2016;12(6):1454-1468.
29. Brown B, Gabra MI, Pellman H. Reasons for acceptance or refusal of human papillomavirus vaccine in a California pediatric practice. Papillomavirus Res. 2017;3:42-45.
30. Gollust SE, LoRusso SM, Nagler RH, Fowler EF. Understanding the role of the news media in HPV vaccine uptake in the United States: synthesis and commentary. Hum Vacc Immunother. 2016;12(6):1430-1434.
31. Rolnick SJ, Parker ED, Nordin JD, et al. Self-report compared to electronic medical record across eight adult vaccines: Do results vary by demographic factors?. Vaccine. 2013;31(37):3928–3935.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Fokom Domgue J, Cunningham SA, Yu RK, Shete S. Reasons for not receiving the HPV vaccine among eligible adults: Lack of knowledge and of provider recommendations contribute more than safety and insurance concerns. Cancer Med. 2020;9:5281–5290. https://doi.org/10.1002/cam4.3192